Media.Player

Monitoring Atherosclerosis Regression, Plaque Stabilization, and Cardiovascular Risk Using a Novel Method to Quantify Oxidized Phospholipids

Technology Benefits

Fully developed technology, having been demonstrated in multiple studies. Technology can be adopted to use other antibodies of high affinity to oxidized phospholipids. Suitable for monitoring the effect of therapeutic intervention studies of patient or model populations.

Technology Application

Offers a high-throughput method to monitor atherosclerosis regression, plaque stabilization, and cardiovascular risk.

Detailed Technology Description

This invention provides a high-throughput in vitro assay [enzyme linked immunoassay] to measure oxidized phospholipds on HDL, HDL-related lipoproteins, and mimetics as a method of estimating reverse oxidized phospholipid transport or plaque stabilization and regression. This technology has been optimized to quantitatively estimate reverse oxidized phospholipid transport and monitor plaque stabilization and regression in studies of rabbits, non-human primates, and human populations.

Supplementary Information

Patent Number: US20120035074A1
Application Number: US13262597A
Inventor: Witztum, Joseph L. | Tsimikas, Sotirios | Miller, Elizabeth
Priority Date: 3 Apr 2009
Priority Number: US20120035074A1
Application Date: 30 Sep 2011
Publication Date: 9 Feb 2012
IPC Current: C40B003004 | C40B004010 | G01N0033566 | G01N0033577
US Class: 506009 | 43500792 | 506018
Assignee Applicant: The Regents of the University of California
Title: METHODS TO DETERMINE ATHEROSCLEROSIS REGRESSION, PLAQUE STABILIZTION AND CARDIOVASCULAR RISK
Usefulness: METHODS TO DETERMINE ATHEROSCLEROSIS REGRESSION, PLAQUE STABILIZTION AND CARDIOVASCULAR RISK
Summary: For determining whether a therapy is effective for treating coronary artery disease or promoting reverse cholesterol transport; for identifying plaque regression or stabilization in a blood vessel in a subject, where the subject is human (all claimed); for measuring the efficacy of drug therapies to treat atherosclerosis (such as statins and niacins); for predicting cardiovascular risk or the increase in oxPL/apoA may by a marker of plaque stabilization or atherosclerosis regression; for diagnostic purposes and for monitoring the effects of dietary interventions; and for monitoring treatment for reducing cholesterol and high low density lipoprotein (LDL) levels using drugs such as statins.
Novelty: Determining whether therapy effective for treating coronary artery disease or promoting reverse cholesterol transport, involves determining oxidized phospholipids/apolipoprotein A ratio in sample from subject before and after therapy

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Application No.

8883428

Others

Related Materials

1. Arai K, Luke MM, Koschinsky ML, Miller ER, Pullinger CR, Witztum JL, Kane JP, Tsimikas S. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis. 2010 Apr;209(2):498-503.
2. Ahmadi N, Tsimikas S, Hajsadeghi F, Saeed A, Nabavi V, Bevinal MA, Kadakia J, Flores F, Ebrahimi R, Budoff MJ. Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium. Am J Cardiol. 2010 Feb 15;105(4):459-66.

Tech ID/UC Case

19200/2009-236-0

Related Cases

2009-236-0, 2005-037-1, 2005-037-2

*Abstract

It is known that oxidized phospholipids are pre-inflammatory and pro-atherogenic and that high-density lipoproteins (HDL)—or its lipoprotein also called apolipoprotein-A—is involved in mediating reverse cholesterol transport. Currently there is no accepted method for high-throughput measurement of reverse cholesterol transport or reverse-oxidized phospholipid transport.

*IP Issue Date

Nov 11, 2014

*Principal Investigator

Name: Elizabeth Miller

Department:

Name: Sotirios Tsimikas

Department:

Name: Joseph Witztum

Department:

Country/Region

USA